Although systematic research in the area of nausea and vomiting began in the late 1950s, the main impetus in this field of research has been development of receptor selective antiemetics such as the first- and second-generation serotonin 5-HT3 and substance P neurokinin NK1 receptor antagonists combined with the glucocorticoid dexamethasone, which protect up to 80–90% of cancer patients from vomiting who were prescribed highly emetogenic cytotoxic chemotherapeutic regimens such as cisplatin. The gene discussed is HTR3A; the disease is cancer.